SCHEMBL13819985

SCHEMBL13819985

COc1ccc(-c2nc(C(N)=O)co2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 7/20 0.70
HDAC8 Q9BY41 7/20 0.70
HDAC6 Q9UBN7 7/20 0.70
ALDH1A1 P00352 3/20 0.65
PDE4B Q07343 4/20 0.60
PDE4D Q08499 3/20 0.60
IKBKB O14920 1/20 0.56
ENPP3 O14638 1/20 0.51
ENPP1 P22413 1/20 0.51
KMT2A Q03164 1/20 0.47
GRM2 Q14416 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
PARP1 P09874 1/20 0.46
PARP10 Q53GL7 1/20 0.46
PARP2 Q9UGN5 1/20 0.46
PARP4 Q9UKK3 1/20 0.46
APP P05067 1/20 0.45
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31604697 0.86 HDAC1 (0.72) HDAC1HDAC8HDAC6ALDH1A1PDE4B
SCHEMBL25002914 0.85 HDAC1 (0.74) HDAC1HDAC8HDAC6ALDH1A1PDE4B
SCHEMBL25003155 0.84 HDAC1 (0.78) HDAC1HDAC8HDAC6ALDH1A1PDE4B
SCHEMBL28033118 0.83 ALDH1A1 (0.71) HDAC1HDAC8HDAC6ALDH1A1PDE4B
Hydrochloric Acid SCHEMBL28034372 0.81 ALDH1A1 (0.56) HDAC1HDAC8HDAC6ALDH1A1PDE4B
SCHEMBL1385110 0.81 ALDH1A1 (0.60) HDAC1HDAC8HDAC6ALDH1A1PDE4B
SCHEMBL27808017 0.81 ALDH1A1 (0.73) HDAC1HDAC8HDAC6ALDH1A1PDE4B
SCHEMBL21689255 0.81 ALDH1A1 (0.73) HDAC1HDAC8HDAC6ALDH1A1PDE4B
SCHEMBL18207866 0.80 MKNK1 (0.56) HDAC1HDAC8HDAC6ALDH1A1PDE4B
SCHEMBL17055727 0.80 HDAC1 (0.64) HDAC1HDAC8HDAC6PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729270-B2 Anti-cancer compounds, synthesis thereof, and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (US) 2014-05-20 US disclosed
US-8729270-B2 Anti-cancer compounds, synthesis thereof, and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (US) 2014-05-20 US disclosed
US-20120289704-A1 ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2012-11-15 US disclosed
US-20120289704-A1 ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2012-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289704-A1 ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME MCL1, BRDT, GLS HDAC1 1633/4885HDAC8 691/4885HDAC6 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.